TARRYTOWN, N.Y., April 12, 2021 /PRNewswire/ --
REGEN-COV rapidly protected household contacts from exposure
to SARS-CoV-2 at home, with 72% protection against symptomatic
infections in the first week, and 93% in subsequent weeks
Among individuals who developed symptomatic infections,
REGEN-COV recipients cleared the virus faster and had much shorter
symptom duration
Regeneron will share data with U.S. FDA and request EUA
expansion to include COVID prevention for appropriate populations,
using a 1,200 mg subcutaneous dose
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced
positive results from a Phase 3 trial (2069A) assessing the ability
of REGEN-COV™ (casirivimab with imdevimab) to reduce the risk and
burden of COVID-19 infection among household contacts of SARS-CoV-2
infected individuals. The trial, which was jointly run with the
National Institute of Allergy and Infectious Diseases (NIAID), part
of the National Institutes of Health (NIH), met its primary and key
secondary endpoints, showing that REGEN-COV 1,200 mg administered
subcutaneously (SC) reduced the risk of symptomatic infections by
81% in those who were not infected when they entered the trial.
"These data suggest that REGEN-COV can complement widespread
vaccination strategies, particularly for those at high risk of
infection. Importantly, to date REGEN-COV has been shown in
vitro to retain its potency against emerging COVID-19 variants
of concern," said Myron Cohen, M.D.,
who leads the monoclonal antibody efforts for the NIH-sponsored
COVID Prevention Network (CoVPN) and is Director of the Institute
for Global Health & Infectious Diseases at the University of North Carolina at Chapel Hill.
"Despite standard precautions to reduce transmission, nearly 10% of
unvaccinated individuals living with an infected person developed
symptomatic infections if they did not receive REGEN-COV. If
authorized, convenient subcutaneous administration of REGEN-COV
could help control outbreaks in high-risk settings where
individuals have not yet been vaccinated, including individual
households and group living settings."
The Phase 3, double-blind, placebo-controlled trial assessed the
effect of REGEN-COV on uninfected individuals without
anti-SARS-CoV-2 antibodies or any COVID-19 symptoms, who lived in
the same household as an individual who tested positive for
SARS-CoV-2 within the prior 4 days. The trial enrolled 1,505 people
who were not infected with SARS-CoV-2 at baseline and randomized to
receive either 1 dose of REGEN-COV (1,200 mg) or placebo,
administered as SC injections.
"These findings are very encouraging and suggest that REGEN-COV
is highly effective at preventing symptomatic COVID-19 in household
contacts of SARS-CoV-2 infected individuals," said Dan H. Barouch, M.D., Ph.D., co-principal
investigator of the trial and Director of the Center for Virology
and Vaccine Research at Beth Israel Deaconess Medical Center and
Professor of Medicine at Harvard Medical
School. "The rapid and robust protection, together with the
subcutaneous route of administration, support the practical utility
of these antibodies in protecting against COVID-19 in multiple
settings, including after high-risk exposures. These antibodies may
be particularly useful in individuals who are not yet vaccinated,
and may also have potential in those who are immunosuppressed and
may not respond well to vaccines."
On average, individuals treated with REGEN-COV who experienced a
symptomatic infection resolved their symptoms in 1 week, compared
to 3 weeks with placebo. Infected individuals also cleared the
virus faster with REGEN-COV.
"With more than 60,000 Americans continuing to be diagnosed with
COVID-19 every day, the REGEN-COV antibody cocktail may help
provide immediate protection to unvaccinated people who are exposed
to the virus, and we are also working to understand its potential
to provide ongoing protection for immunocompromised patients who
may not respond well to vaccines," said George D. Yancopoulos, M.D., Ph.D., President
and Chief Scientific Officer at Regeneron. "We thank the
individuals, investigators and our collaborators involved in the
trial, and look forward to rapidly discussing these results with
regulatory authorities."
TABLE: Key Results
from Phase 3 Trial for the Prevention of
COVID-19 in
Uninfected Individuals1
|
|
|
REGEN-COV
(single 1,200 mg
dose)
|
Placebo
|
n=753
|
n=752
|
Risk of
symptomatic SARS-CoV-2 infection
|
Through day 29
(primary endpoint)
|
Risk
reduction
|
81%
(p<0.0001)
|
# of patients with
events
|
11 (1.5%)
|
59 (7.8%)
|
Within 1
week2
|
Risk
reduction
|
72%
(nominal
p=0.0002)
|
# of individuals with
events
|
9 (1.2%)
|
32 (4.3%)
|
Post-1
week2
|
Risk
reduction
|
93%
(nominal
p<0.0001)
|
# of individuals with
events
|
2 (0.3%)
|
27 (3.6%)
|
Symptoms and viral
load
|
Total weeks with
symptoms
|
Reduction
|
93%
(p<0.0001)
|
Total # of weeks
(cumulative for all individuals in each arm)
|
13
|
188
|
# of weeks with
symptoms (average) in symptomatic individuals
|
1.2
|
3.2
|
Total weeks with
high viral load (>104 copies/mL)
|
Reduction
|
90%
(p<0.0001)
|
Total # of weeks
(cumulative for all individuals in each arm)
|
14
|
136
|
# of weeks with high
viral load (average) in qPCR positive subjects
|
0.4
|
1.3
|
1.
|
Based on the
seronegative modified Full Analysis Set population, which includes
all randomized subjects without evidence of current or prior
SARS-CoV-2 infection (i.e., a negative RT-qPCR test and a negative
antibody test) at randomization
|
2.
|
These analyses were
not part of the pre-planned statistical analysis plan, so p-values
are nominal
|
Adverse events (AEs) occurred in 20% (n=265 out of 1,311) of
REGEN-COV participants and 29% (n=379 out of 1,306) of placebo
participants, and serious AEs occurred in 1% (n=10) of REGEN-COV
and 1% (n=15) of placebo participants. There were 0 REGEN-COV and 4
placebo participants who were either hospitalized or visited the
emergency room because of COVID-19 during the 29-day efficacy
assessment period. Injection site reactions, all of which were
grades 1-2, occurred in 4% (n=55) of REGEN-COV and 2% (n=19) of
placebo participants. No individuals from either group withdrew
from the trial due to AEs, and none of the deaths in the trial (2
REGEN-COV, 2 placebo) were attributed to COVID-19 or study
drug.
REGEN-COV continues to be evaluated in clinical trials in
multiple settings for COVID-19: for the prevention of COVID-19 in
household contacts of infected individuals, and in non-hospitalized
and certain hospitalized patients, including the open-label
RECOVERY trial of hospitalized patients in the UK. As of
April 2021, more than 25,000 people
have participated in clinical trials involving REGEN-COV.
The development and manufacturing of REGEN-COV have been funded
in part with federal funds from the Biomedical Advanced Research
and Development Authority (BARDA), part of the U.S. Department of
Health and Human Services, Office of the Assistant Secretary for
Preparedness and Response, under OT number: HHSO100201700020C.
About the Multi-part Phase 3 Trial
To
qualify for the joint Regeneron/NIAID multi-part Phase 3 trial, all
participants were enrolled without any COVID-19 symptoms
(asymptomatic) and lived in the same household as an individual who
tested positive for SARS-CoV-2 within the prior 4 days. All
participants were tested for SARS-CoV-2 at baseline using a RT-qPCR
test from nasopharyngeal swabs. Participants with a negative test
result joined the prevention trial (2069A) and participants with a
positive test result joined the treatment trial (2069B).
All participants were then randomized (1:1) to receive either 1
dose of REGEN-COV (1,200 mg) or placebo, administered via 4 SC
injections.
Among participants enrolled in the prevention trial, 41% were
Latino/Hispanic and 9% were Black/African American. In total, 31%
of participants had at least one known factor that put them at high
risk of suffering severe consequences from COVID-19, as defined in
the REGEN-COV fact sheet. In addition, 33% were obese and 38% were
aged ³50 years (median age: 44 years; range: 12-92 years).
About the REGEN-COV Antibody Cocktail
REGEN-COV
(casirivimab with imdevimab) is a cocktail of two monoclonal
antibodies (also known as REGN10933 and REGN10987) that was
designed specifically to block infectivity of SARS-CoV-2, the virus
that causes COVID-19, using Regeneron's proprietary
VelocImmune® and VelociSuite®
technologies. The two potent, virus-neutralizing antibodies that
form the cocktail bind non-competitively to the critical receptor
binding domain of the virus's spike protein, which diminishes the
ability of mutant viruses to escape treatment and protects against
spike variants that have arisen in the human population, as
detailed in Science.
Under an EUA issued by the U.S. Food and Drug
Administration (FDA), REGEN-COV is currently available in the U.S.
to treat mild-to-moderate COVID-19 in adults, as well as in
pediatric patients at least 12 years of age and weighing at least
40 kg, who have received positive results of direct SARS-CoV-2
viral testing and are at high risk for progressing to severe
COVID-19 and/or hospitalization. REGEN-COV has not been approved by
the FDA but has been authorized for emergency use. This use is
authorized only for the duration of the declaration that
circumstances exist justifying the authorization of the emergency
use under section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1),
unless the authorization is terminated or revoked sooner.
REGEN-COV is currently authorized and available in a 2,400 mg IV
dose, with infusion times as short as 20 minutes. The criteria for
'high-risk' patients are described in the Fact Sheet for
Healthcare Providers. In the U.S., REGEN-COV is not authorized for
use in patients who are hospitalized due to COVID-19 or require
oxygen therapy, or for people currently using chronic oxygen
therapy because of an underlying comorbidity who require an
increase in baseline oxygen flow rate due to COVID-19.
Under this EUA, REGEN-COV is available throughout the U.S. –
information on availability in your area is available from the
Department of Health and Human Services and the National Infusion
Center Association.
Regeneron is collaborating with Roche to increase global
supply of REGEN-COV. Regeneron is responsible for development and
distribution of the treatment in the U.S., and Roche is primarily
responsible for development and distribution outside the U.S. The
companies share a commitment to making the antibody cocktail
available to COVID-19 patients around the globe and will support
access in low- and lower-middle-income countries through drug
donations to be made in partnership with public health
organizations.
About Regeneron's VelocImmune Technology
Regeneron's VelocImmune technology utilizes a proprietary
genetically engineered mouse platform endowed with a genetically
humanized immune system to produce optimized fully human
antibodies. When Regeneron's co-Founder, President and Chief
Scientific Officer George D.
Yancopoulos was a graduate student with his mentor
Frederick W. Alt in 1985, they were
the first to envision making such a genetically humanized
mouse, and Regeneron has spent decades inventing and developing
VelocImmune and related VelociSuite technologies. Dr.
Yancopoulos and his team have used VelocImmune technology to
create approximately a quarter of all original, FDA-approved fully
human monoclonal antibodies currently available. This includes
REGEN-COVTM (casirivimab with imdevimab),
Dupixent® (dupilumab), Libtayo®
(cemiplimab-rwlc), Praluent® (alirocumab),
Kevzara® (sarilumab), Evkeeza™ (evinacumab-dgnb) and
Inmazeb™ (atoltivimab, maftivimab and odesivimab-ebgn).
AUTHORIZED USE AND IMPORTANT SAFETY INFORMATION
Authorized Emergency Use
REGEN-COV, (casirivimab with
imdevimab to be administered together) is authorized for the
treatment of mild to moderate coronavirus disease 2019 (COVID-19)
in adults and pediatric patients (12 years of age and older
weighing at least 40 kg) with positive results of direct SARS-CoV-2
viral testing, and who are at high risk for progressing to severe
COVID-19 and/or hospitalization. [see Limitations of Authorized
Use]
- REGEN-COV has not been approved, but has been authorized for
emergency use by FDA
- This use is authorized only for the duration of the declaration
that circumstances exist justifying the authorization of the
emergency use under section 564(b)(1) of the Act, 21 U.S.C. §
360bbb-3(b)(1), unless the authorization is terminated or revoked
sooner
- Healthcare providers should review the Fact Sheet for
Healthcare Providers for information on the authorized use of
REGEN-COV and mandatory requirements of the EUA and must comply
with the requirements of the EUA. The FDA Letter of
Authorization is available for reference, as well as the
Dear Healthcare Provider Letter and Patient Fact
Sheet
Limitations of Authorized Use
- REGEN-COV (casirivimab with imdevimab) is not authorized for
use in patients:
-
- who are hospitalized due to COVID-19, OR
- who require oxygen therapy due to COVID-19, OR
- who require an increase in baseline oxygen flow rate due to
COVID-19 in those on chronic oxygen therapy due to underlying
non-COVID-19 related comorbidity
- Benefit of treatment with REGEN-COV has not been observed in
patients hospitalized due to COVID-19. Monoclonal antibodies, such
as REGEN-COV, may be associated with worse clinical outcomes when
administered to hospitalized patients with COVID-19 requiring high
flow oxygen or mechanical ventilation.
Definition of High-Risk Patients
High-risk is defined
as patients who meet at least one of the following criteria:
- Have a body mass index (BMI) ≥35
- Have chronic kidney disease
- Have diabetes
- Have immunosuppressive disease
- Are currently receiving immunosuppressive treatment
- Are ≥65 years of age
- Are ≥55 years of age AND have
-
- cardiovascular disease, OR
- hypertension, OR
- chronic obstructive pulmonary disease/other chronic respiratory
disease.
- Are 12 – 17 years of age AND have
-
- BMI ≥85th percentile for their age and gender based on CDC
growth charts,
https://www.cdc.gov/growthcharts/clinical_charts.htm, OR
- sickle cell disease, OR
- congenital or acquired heart disease, OR
- neurodevelopmental disorders (e.g., cerebral palsy), OR
- a medical-related technological dependence, for example,
tracheostomy, gastrostomy, or positive pressure ventilation (not
related to COVID-19), OR
- asthma, reactive airway or other chronic respiratory disease
that requires daily medication for control.
Circulating SARS-CoV-2 viral variants may be associated with
resistance to monoclonal antibodies. Healthcare providers should
review the Antiviral Resistance information in Section 15 of the
Fact Sheet for details regarding specific variants and resistance,
and refer to the CDC website
(https://www.cdc.gov/coronavirus/2019-ncov/transmission/variant-cases.html)
as well as information from state and local health authorities
regarding reports of viral variants of importance in their region
to guide treatment decisions.
IMPORTANT SAFETY INFORMATION
REGEN-COV (casirivimab
with imdevimab) is an unapproved investigational therapy, and there
are limited clinical data available. Serious and unexpected adverse
events may occur that have not been previously reported with
REGEN-COV use.
Warnings and Precautions:
- Hypersensitivity Including Anaphylaxis and Infusion-Related
Reactions: There is a potential for serious
hypersensitivity reaction, including anaphylaxis, with
administration of REGEN-COV. If signs or symptoms of a clinically
significant hypersensitivity reaction or anaphylaxis occur,
immediately discontinue administration and initiate appropriate
medications and/or supportive therapy. Infusion-related reactions
have been observed with administration of REGEN-COV.
-
- Signs and symptoms of infusion related reactions may
include fever, difficulty breathing, reduced oxygen
saturation, chills, nausea, arrythmia (e.g., atrial fibrillation,
tachycardia, bradycardia), chest pain or discomfort, weakness,
altered mental status, headache, bronchospasm, hypotension,
hypertension, angioedema, throat irritation, rash including
urticaria, pruritus, myalgia, dizziness, fatigue and diaphoresis.
If an infusion-related reaction occurs, consider slowing or
stopping the infusion and administer appropriate medications and/or
supportive care
- Clinical Worsening After REGEN-COV Administration:
Clinical worsening of COVID-19 after administration of REGEN-COV
has been reported and may include signs or symptoms of fever,
hypoxia or increased respiratory difficulty, arrythmia (e.g.,
atrial fibrillation, tachycardia, bradycardia), fatigue, and
altered mental status. Some of these events required
hospitalization. It is not known if these events were related to
REGEN-COV use or were due to progression of COVID-19.
- Limitations of Benefit and Potential for Risk in Patients
with Severe COVID-19: Benefit of treatment with REGEN-COV
has not been observed in patients hospitalized due to COVID-19.
Monoclonal antibodies, such as REGEN-COV, may be associated with
worse clinical outcomes when administered to hospitalized patients
with COVID-19 requiring high-flow oxygen or mechanical ventilation.
Therefore, REGEN-COV is not authorized for use in patients who are
hospitalized due to COVID-19, OR who require oxygen therapy due to
COVID-19, OR who require an increase in baseline oxygen flow rate
due to COVID-19 in those on chronic oxygen therapy due to
underlying non-COVID-19 related comorbidity.
Adverse Reactions:
- Serious adverse events (SAEs) were reported in 4 (1.6%)
patients in REGEN-COV 2,400 mg group, 2 (0.8%) patients in
REGEN-COV 8,000 mg group and 6 (2.3%) patients in the placebo
group. None of the SAEs were considered to be related to study
drug. SAEs that were reported as Grade 3 or 4 adverse events were
pneumonia, hyperglycemia, nausea and vomiting (2,400 mg REGEN-COV),
intestinal obstruction and dyspnea (8,000 mg REGEN-COV) and
COVID-19, pneumonia and hypoxia (placebo). REGEN-COV is
not authorized at the 8,000 mg dose (4,000 mg casirivimab and
4,000 mg imdevimab).
- One anaphylactic reaction was reported in the clinical program.
The event began within 1 hour of completion of the infusion, and
required treatment including epinephrine. The event resolved.
Infusion-related reactions, of Grade 2 or higher severity, were
reported in 4 subjects (1.5%) in the 8,000 mg (4,000 mg casirivimab
and 4,000 mg imdevimab) arm. These infusion-related reactions
events were moderate in severity; and include pyrexia, chills,
urticaria, pruritus, abdominal pain, and flushing. One
infusion-related reaction (nausea) was reported in the placebo arm
and none were reported in the 2,400 mg (1,200 mg casirivimab and
1,200 mg imdevimab) arm. In two subjects receiving the 8,000 mg
dose of REGEN-COV, the infusion-related reactions (urticaria,
pruritus, flushing, pyrexia, shortness of breath, chest tightness,
nausea, vomiting) resulted in permanent discontinuation of the
infusion. All events resolved.
Patient Monitoring Recommendations: Clinically monitor
patients during infusion and observe patients for at least 1 hour
after infusion is complete.
Use in Specific Populations:
- Pregnancy: There is currently limited clinical
experience in the use of REGEN-COV in COVID-19 patients who are
pregnant. REGEN-COV therapy should be used during pregnancy only if
the potential benefit justifies the potential risk for the mother
and the fetus.
- Lactation: There is currently no clinical
experience in use of REGEN-COV in COVID-19 patients who are
breastfeeding. The development and health benefits of breastfeeding
should be considered along with the mother's clinical need for
REGEN-COV and any potential adverse effects on the breastfed child
from REGEN-COV or from the underlying maternal condition.
About Regeneron
Regeneron (NASDAQ: REGN) is a
leading biotechnology company that invents life-transforming
medicines for people with serious diseases. Founded and led for
over 30 years by physician-scientists, our unique ability to
repeatedly and consistently translate science into medicine has led
to nine FDA-approved treatments and numerous product candidates in
development, almost all of which were homegrown in our
laboratories. Our medicines and pipeline are designed to help
patients with eye diseases, allergic and inflammatory diseases,
cancer, cardiovascular and metabolic diseases, pain, hematology,
infectious diseases and rare diseases.
Regeneron is accelerating and improving the traditional drug
development process through our proprietary VelociSuite
technologies, such as VelocImmune, which uses unique
genetically humanized mice to produce optimized fully human
antibodies and bispecific antibodies, and through ambitious
research initiatives such as the Regeneron Genetics Center, which
is conducting one of the largest genetics sequencing efforts in the
world. For additional information about the company, please visit
www.regeneron.com or follow @Regeneron on Twitter.
Forward-Looking Statements and Use of Digital
Media
This press release includes forward-looking statements that
involve risks and uncertainties relating to future events and the
future performance of Regeneron Pharmaceuticals, Inc. ("Regeneron"
or the "Company"), and actual events or results may differ
materially from these forward-looking statements. Words such as
"anticipate," "expect," "intend," "plan," "believe," "seek,"
"estimate," variations of such words, and similar expressions are
intended to identify such forward-looking statements, although not
all forward-looking statements contain these identifying words.
These statements concern, and these risks and uncertainties
include, among others, the impact of SARS-CoV-2 (the virus that has
caused the COVID-19 pandemic) on Regeneron's business and its
employees, collaborators, and suppliers and other third parties on
which Regeneron relies, Regeneron's and its collaborators' ability
to continue to conduct research and clinical programs, Regeneron's
ability to manage its supply chain, net product sales of products
marketed or otherwise commercialized by Regeneron and/or its
collaborators (collectively, "Regeneron's Products"), and the
global economy; the nature, timing, and possible success and
therapeutic applications of Regeneron's Products and product
candidates and research and clinical programs now underway or
planned, including without limitation the development program
relating to REGEN-COVTM (casirivimab with imdevimab)
antibody cocktail; how long the Emergency Use Authorization ("EUA")
granted by the U.S. Food and Drug Administration (the "FDA") for
REGEN-COV will remain in effect and whether the EUA is revoked by
the FDA based on its determination that the underlying health
emergency no longer exists or warrants such authorization or other
reasons; the likelihood, timing, and scope of possible regulatory
approval and commercial launch of Regeneron's product candidates
(such as REGEN-COV) and new indications for Regeneron's Products;
whether, based on the data discussed in this press release or
otherwise, the EUA for REGEN-COV will be expanded to include
COVID-19 prevention for appropriate populations and/or include the
1,200 mg subcutaneous dose of REGEN-COV; the ability of Regeneron's
collaborators, suppliers, or other third parties (as applicable) to
perform manufacturing, filling, finishing, packaging, labeling,
distribution, and other steps related to Regeneron's Products and
product candidates (including REGEN-COV) and the impact of the
foregoing on Regeneron's ability to supply its Products and product
candidates (including REGEN-COV); the ability of Regeneron to
manage supply chains for multiple products and product candidates;
safety issues resulting from the administration of Regeneron's
Products and product candidates (such as REGEN-COV) in patients,
including serious complications or side effects in connection with
the use of Regeneron's Products and product candidates in clinical
trials; uncertainty of market acceptance and commercial success of
Regeneron's Products and product candidates and the impact of
studies (whether conducted by Regeneron or others and whether
mandated or voluntary) (including the study discussed in this press
release) on any potential regulatory approval (including with
respect to REGEN-COV) and/or the commercial success of Regeneron's
Products and product candidates; determinations by regulatory and
administrative governmental authorities which may delay or restrict
Regeneron's ability to continue to develop or commercialize
Regeneron's Products and product candidates, including without
limitation REGEN-COV; ongoing regulatory obligations and oversight
impacting Regeneron's Products, research and clinical programs, and
business, including those relating to patient privacy; the
availability and extent of reimbursement of Regeneron's Products
from third-party payers, including private payer healthcare and
insurance programs, health maintenance organizations, pharmacy
benefit management companies, and government programs such as
Medicare and Medicaid; coverage and reimbursement determinations by
such payers and new policies and procedures adopted by such payers;
competing drugs and product candidates that may be superior to, or
more cost effective than, Regeneron's Products and product
candidates; the extent to which the results from the research and
development programs conducted by Regeneron and/or its
collaborators may be replicated in other studies and/or lead to
advancement of product candidates to clinical trials, therapeutic
applications, or regulatory approval; unanticipated expenses; the
costs of developing, producing, and selling products; the ability
of Regeneron to meet any of its financial projections or guidance
and changes to the assumptions underlying those projections or
guidance; the potential for any license, collaboration, or supply
agreement, including Regeneron's agreements with Sanofi, Bayer, and
Teva Pharmaceutical Industries Ltd. (or their respective affiliated
companies, as applicable), as well as Regeneron's collaboration
with Roche relating to REGEN-COV, to be cancelled or terminated;
and risks associated with intellectual property of other parties
and pending or future litigation relating thereto (including
without limitation the patent litigation and other related
proceedings relating to EYLEA® (aflibercept) Injection,
Dupixent® (dupilumab), Praluent®
(alirocumab), and REGEN-COV), other litigation and other
proceedings and government investigations relating to the Company
and/or its operations, the ultimate outcome of any such proceedings
and investigations, and the impact any of the foregoing may have on
Regeneron's business, prospects, operating results, and financial
condition. A more complete description of these and other material
risks can be found in Regeneron's filings with the U.S. Securities
and Exchange Commission, including its Form 10-K for the year ended
December 31, 2020. Any
forward-looking statements are made based on management's current
beliefs and judgment, and the reader is cautioned not to rely on
any forward-looking statements made by Regeneron. Regeneron does
not undertake any obligation to update (publicly or otherwise) any
forward-looking statement, including without limitation any
financial projection or guidance, whether as a result of new
information, future events, or otherwise.
Regeneron uses its media and investor relations website and
social media outlets to publish important information about the
Company, including information that may be deemed material to
investors. Financial and other information about Regeneron is
routinely posted and is accessible on Regeneron's media and
investor relations website (http://newsroom.regeneron.com) and its
Twitter feed (http://twitter.com/regeneron).
Regeneron
Contacts:
Media
Relations
Sarah
Cornhill
media@regeneron.com
|
Investor
Relations
Vesna
Tosic
investor@regeneron.com
|
View original
content:http://www.prnewswire.com/news-releases/phase-3-prevention-trial-showed-81-reduced-risk-of-symptomatic-sars-cov-2-infections-with-subcutaneous-administration-of-regen-cov-casirivimab-with-imdevimab-301266366.html
SOURCE Regeneron Pharmaceuticals, Inc.